CLINICAL CHARACTERISTICS OF RESPIRATORY INVOLVEMENT IN CHILDREN WITH CYSTIC FIBROSIS IN THE CHUVASH REPUBLIC

CLINICAL CHARACTERISTICS OF RESPIRATORY INVOLVEMENT IN CHILDREN WITH CYSTIC FIBROSIS IN THE CHUVASH REPUBLIC

Cystic fibrosis is a common hereditary disease, characterized by multiple organ dysfunction, including early and severe involvement of respiratory system. The disease is caused by CFTR (cystic fibrosis transmembrane conductance regulator) gene mutation. Respiratory tract involvement is a main factor...

Full description

Bibliographic Details
Main Authors:	O. I. Golubtsova, S. A. Krasovskiy, S. L. Kozhevnikova, N. I. Kapranov
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2012-07-01
Series:	Вопросы современной педиатрии
Subjects:	cystic fibrosis children chronic nonspecific pulmonary diseases molecular genetic assay «mild» mutation e92k «severe» mutation f508 del dornase alpha
Online Access:	https://vsp.spr-journal.ru/jour/article/view/454

Similar Items

Common CFTR gene mutations in cystic fibrosis patients in Mazandaran province - Iran
by: Haleh Akhavan-Niaki (PhD), et al.
Published: (2008-10-01)

INFLUENCE OF THE AGE OF THE DIAGNOSIS AND THE BEGINNING OF SPECIFIC THERAPY ON MAIN CLINICAL AND LABORATORY MANIFESTATIONS OF A DISEASE IN PATIENTS WITH CYSTIC FIBROSIS
by: S. A. Krasovskii, et al.
Published: (2014-03-01)

LONG TERM MUCOLYTIC THERAPY WITH DORNASE ALFA AT NOVOSIBIRSK CENTER FOR DIAGNOSTICS, TREATMENT, RHEABILITATION AND ADAPTATION OF CHILDREN WITH CYSTIC FIBROSIS
by: N.I. Romanenko, et al.
Published: (2006-03-01)

LONG TERM MUCOLYTIC THERAPY WITH DORNASE ALFA AT NOVOSIBIRSK CENTER FOR DIAGNOSTICS, TREATMENT, RHEABILITATION AND ADAPTATION OF CHILDREN WITH CYSTIC FIBROSIS
by: N.I. Romanenko, et al.
Published: (2006-01-01)

Frequency of 8 CFTR gene mutations in cystic fibrosis patients in Minas Gerais, Brazil, diagnosed by neonatal screening
by: C. Perone, et al.
Published: (2010-02-01)

Trends in Life Expectancy of Cystic Fibrosis Patients in Moscow and their Connection with the Treatment Received: Retrospective Analysis for 1993–2013
by: N. Yu. Kashirskaya, et al.
Published: (2015-09-01)

Cost-utility Analysis of Dornase alfa in comparison with Tobramycin for Managing Iranian Patients with Cystic Fibrosis
by: Fatemeh Sadat Heydari
Published: (2023-04-01)

THE ALGORITHM OF COMPLEX SYNDROME-ORIENTED THERAPY IN CHILDREN WITH CYSTIC FIBROSIS: A MODERN APPROACH
by: Yu. V. Gorinova, et al.
Published: (2013-09-01)

Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
by: Sonia Volpi, et al.
Published: (2022-07-01)

Frequency of the deltaF508 mutation in 108 cystic fibrosis patients in São Paulo: comparison with reported Brazilian data Freqüência da mutação deltaF508 em 108 pacientes com fibrose cística de São Paulo: comparação com dados de estudos brasileiros
by: Thelma Suely Okay, et al.
Published: (2005-04-01)

Clinical and functional control of mucolytic therapy in children with cystic fibrosis
by: O. I. Simonova, et al.
Published: (2022-04-01)

Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)
by: Tomke Sütering, et al.
Published: (2024-12-01)

Analysis of the DF508 mutation in a Brazilian cystic fibrosis population: comparison of pulmonary status of homozygotes with other patients
by: Maróstica P.J.C., et al.
Published: (1998-01-01)

Genetic modification of cystic fibrosis with ΔF508 mutation of CFTR gene using the CRISPR system in peripheral blood mononuclear cells
by: Sepideh Khatibi, et al.
Published: (2021-01-01)

THE NATIONAL CONSENSUS PROJECT* «CYSTIC FIBROSIS: DEFINITION, DIAGNOSTIC CRITERIA, AND THERAPY». SECTION «INHALATION THERAPY» (ABRIDGED)
by: Ye. L. Amelina, et al.
Published: (2014-12-01)

p.F508del in a heterogeneous cystic fibrosis population from Minas Gerais, Brazil
by: P.V.T. Vidigal, et al.
Published: (2008-08-01)

Profile of cystic fibrosis
by: Mona M. El-Falaki, et al.
Published: (2014-09-01)

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients
by: Karin Yaacoby-Bianu, et al.
Published: (2022-10-01)

Cystic fibrosis mutation spectrum in north macedonia: A step toward personalized therapy
by: Terzic M, et al.
Published: (2019-08-01)

Defining a Mutational Panel and Predicting the Prevalence of Cystic Fibrosis in Oman
by: Uwe W. Fass, et al.
Published: (2014-08-01)

Defining a Mutational Panel and Predicting the Prevalence of Cystic Fibrosis in Oman
by: Uwe W. Fass, et al.
Published: (2014-08-01)

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
by: Vito Terlizzi, et al.
Published: (2022-10-01)

DORNASE ALFA IN RUSSIA: 15 YEARS LATER. EFFICACY OF THE DRUG IN THE BASIC TREATMENT IN CHILDREN WITH CYSTIC FIBROSIS
by: O. I. Simonova, et al.
Published: (2012-03-01)

Glycosylation and the cystic fibrosis transmembrane conductance regulator
by: Glick Mary Catherine, et al.
Published: (2001-08-01)

Molecular and Functional Basis of Cystic Fibrosis in Indian Patients: Genetic, Diagnostic and Therapeutic Implications
by: Rajendra Prasad
Published: (2018-10-01)

Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies
by: Saba Anwar, et al.
Published: (2024-07-01)

Genetic pattern of cystic fibrosis patients in Azeri Turkish population
by: Morteza Jabarpoor-Bonyadi, et al.
Published: (2017-03-01)

Phenotype and Genotype of Two Taiwanese Cystic Fibrosis Siblings and a Survey of Delta F508 in East Asians
by: Chao-Jen Lin, et al.
Published: (2008-12-01)

Use of PCR for the determination of the frequency of the deltaF508 mutation in Brasilian cistic fibrosis patients
by: Antonio B. de Miranda, et al.
Published: (1993-06-01)

Molecular analysis of cystic fibrosis patients in Hungary: An update to the mutational spectrum
by: Ivády Gergely, et al.
Published: (2015-01-01)

Genetic and phenotypic traits of children and adolescents with cystic fibrosis in Southern Brazil
by: Katiana Murieli da Rosa, et al.

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy
by: Alice Nicoleta Azoicai, et al.
Published: (2024-05-01)

The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells
by: Raphaël Santinelli, et al.
Published: (2024-01-01)

Cystic Fibrosis Transmembrane Conductance Regulator Folding Mutations Reveal Differences in Corrector Efficacy Linked to Increases in Immature Cystic Fibrosis Transmembrane Conductance Regulator Expression
by: Kathryn W. Peters, et al.
Published: (2021-10-01)

Analysis of CFTR Gene Mutations in Children with Cystic Fibrosis, First Report from North-East of Iran
by: Atieh Mehdizadeh Hakkak, et al.
Published: (2013-08-01)

Genetic screening in cystic fibrosis
by: Chmiel James F, et al.
Published: (2001-03-01)

Molecular analysis using DHPLC of cystic fibrosis: increase of the mutation detection rate among the affected population in Central Italy
by: Nardone Anna, et al.
Published: (2004-04-01)

The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes
by: Sana Hasan, et al.
Published: (2022-09-01)

Respiratory Syncytial Virus Infection Disrupts Monolayer Integrity and Function in Cystic Fibrosis Airway Cells
by: Wayne Sullender, et al.
Published: (2013-09-01)

Structure and function of the cystic fibrosis transmembrane conductance regulator
by: M.M. Morales, et al.
Published: (1999-08-01)